Fosfluconazole (prodif intravenous solution), a therapeutic drug for deep-seated mycosis, that allows reduction in volume load, bolus injection: Basic and clinical aspects

Japanese Pharmacology and Therapeutics

Volumn 33, Issue 4, 2005, Pages 267-302

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIFUNGAL AGENT; FLUCONAZOLE; FOSFLUCONAZOLE; HYDROXYL GROUP; PHOSPHORIC ACID;

AQUEOUS SOLUTION; ASCITES; BOLUS INJECTION; DRUG INDICATION; ESTERIFICATION; FLUID THERAPY; FUNGEMIA; GASTROINTESTINAL INFECTION; HEART FAILURE; HUMAN; MENINGITIS; MYCOSIS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; URINARY TRACT INFECTION;

EID: 21044433358     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
2. Marr KA, Seidel K, Slavin MA, Bowden RA, Gary Schoch H, Flowers MED, et al. Prolonged fluconazole prophylaxix is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96 (6): 2055-61.
3. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994; 20: 522-8.
4. Edward JE Jr, Bodey GP, Bowden RA, Büchner T, de Pauw BE, Filler SG, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
5. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
6. Demajo WA, Guimond J-G, Rotstein C, Tweeddale M, the Canadian Candidemia Advisory Group. Guidelines for the management of nosocomial Candida infections in non-neutropenic intensive care patients. Can J Infecdt Dis 1997; 8 Suppl B: 3B-9B.
7. Jap J Antibiotics 1998; 51 (12): 721-34.
8. Empiric Therapy: Jap J Antibiotics 1997; 50 (8): 669-82.
9. Grant SM, Clissold SP. Fluconazole A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39 (6): 877-916.
10. Berl T, Wilner KD, Gardner M, Hansen RA, Farmer B, Baris BA, et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 1995; 6 (2): 242-7.
11. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990; 29: 221-6.
12. Fluconazole Jap J Antibiotics 1991; 44 (5): 552-61.
13. Fernley HN. Mammalian Alkaline Phosphatases. In: Boyer PD. editor. The Enzymes. 3rd ed. New York: Academic Press; 1971. Vol. 4, p. 417-47.
14. Schultz-Hector S, Balz K, Böhm M, Ikehara Y, Rieke L. Cellular Localization of endothelial alkaline phosphatase reaction product and enzyme protein in the myocardium. J Histochem Cytochem 1993; 41 (12): 1813-21.
15. Nouwen EJ, De Broe ME. Human intestinal versus tissue-nonspecific alkaline phosphatase as complementary urinary markers for the proximal tubule. Kidney International 1994; 46 (Suppl 47): S-43-S-51.
16. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney International 1984; 26: 101-11.
17. Fluconazole Jap J Antibiotics 1989; 42 (1): 63-116.
18. Matsushima T, Kimura M, Nakamura J, Tomizawa S. Effectiveness of fluconazole for pulmonary aspergilloma and its concentration in lung tissue. KAWASAKI Med J 1992; 18 (3-4): 85-92.
19. Force RW. Fluconazole concentrations in breast milk. Pediatr Infect Dis J 1995; 14 (3): 235-6.
20. 14C] fluconazole in humans. Drug Metab Dispos 1991; 19 (4): 764-7.
21. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996; 41: 319-23.
22. Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993; 153: 102-4.
23. Man̂ez R, Martin M, Raman V, Silverman D, Jain A, Warty V, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57 (10): 1521-35.
24. López-Gil JA. Fluconazole-cyclosporine interaction: A dose-dependent effect? Ann Pharmacother 1993; 27: 427-30.
25. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49 (4): 420-5.
26. Fournier JP, Schneider S, Martinez P, Mahagne MH, Ducoeur S, Haffner M, et al. Coma hypoglycémique chez une patiente traitée par glipizide et fluconazole: une possible interaction? Therapie 1992; 47: 446-7.
27. Cato IIIA, Cao G, Hsu A, Cavanaugh J, Leonard J, Granneman R. Drug Metab Dispos 1997; 25 (9): 1104-6.
28. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ. Interaction between fluconazole and midazolam in intensive care patients. Acta Annesthesiol Scand 1999; 43: 509-14.
29. Konishi H, Morita K, Yamaji A. Effect of fluconazole on theophylline disposition in humans. Eur J Clin Pharnacol 1994; 46: 309-12.
30. Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Am J Obstet Gynecol 1998; 178 (2): 300-4.
31. Sahai J, Gallicano K, Pakuts A, Cameron DW. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994; 169 (5): 1103-7.
32. Apseloff G, Hilligoss DM, Gardner MJ, Henry EB, Inskeep PB, Gerber N, et al. Induction of fluconazole metabolism by rifampin: In vivo study in humans. J Clin Pharmacol 1991; 31: 358-61.